printemailclick to share buttonfacebooktwitterlinkedin
Molecular Oncology

The Molecular Oncology Advisory Committee (MOAC) reviews current and emerging knowledge and makes recommendations on the optimal application of molecular testing for cancer risk, diagnosis, monitoring, prognosis or prediction of response to treatment for the benefit of Ontarians and Ontario cancer patients. The PEBC works with MOAC to identify and summarize evidence on specific topics and to make recommendations for cancer control in Ontario.

Find out more about the Molecular Oncology Advisory Committee

The PEBC has a formal and standardized process to ensure the currency of each document (please see the PEBC Assessment & Review Protocol for more information). This process guides clinical experts to assess a document’s current status and relevance. A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance. The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( or the lead author of the document.

Evidence Summaries

  • Screening for Lynch Syndrome by Immunohistochemistry BRAF Mutations Analysis and MLH1 Promoter Methylation Analysis for Patients in Ontario with Colorectal or Endometrial Cancers
    Evidence Summary MOAC 3: September 2015
    Status: CURRENT

Recommendation Reports

  • Cancer Care Ontario Sequence Variants in Hereditary Cancers Guideline: An Endorsement of the 2015 Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
    Guideline Endorsement MOTAC-5
    Status: CURRENT
  • Clinical Utility of Multigene Profiling Assays in Invasive Early-Stage Breast Cancer
    Recommendation Report MOAC 4: June 2016
    Status: CURRENT
  • The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia
    Recommendation Report MOAC 1: November 2013
    Status: CURRENT
Last modified: Fri, Sep 15, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?